SCHEMBL22845341

SCHEMBL22845341

NC(=O)c1ccc(-n2c(=O)c3c(n4ncc(NCc5ccccc5)c24)CN(C(=O)c2ccc(Cl)c(Cl)c2)CC3)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PREP P48147 1/20 0.37
LMNA P02545 5/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
HTT P42858 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.35
JAK3 P52333 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
GRM1 Q13255 3/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
MTHFD2 P13995 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845368 0.95 PREP (0.40) PREPLMNAMAPTALDH1A1GAA
SCHEMBL22845317 0.94 PREP (0.36) PREPSMN1; SMN2JAK3IRAK4GRM1
SCHEMBL22845379 0.91 PREP (0.36) PREPLMNAMAPTALDH1A1GAA
SCHEMBL22845325 0.91 MAPT (0.41) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL22845388 0.85 PREP (0.35) PREPSMN1; SMN2GRM1CA12CA1
SCHEMBL22845287 0.84 LMNA (0.37) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845369 0.84 NPY2R (0.39) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845202 0.84 LMNA (0.40) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845286 0.82 LMNA (0.40) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845327 0.82 TACR3 (0.40) LMNAMAPTALDH1A1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL PREP 966/4885LMNA 1680/4885MAPT 651/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL PREP 966/4885LMNA 1680/4885MAPT 651/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL PREP 966/4885LMNA 1680/4885MAPT 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.